June 11th, 2012 // 12:52 pm @ jmpickett
A US appeals court has judged failure to report FDA Form 483s can mislead investors in its revival of a case against KV Pharmaceutical.
Damage Control! How to Handle an FDA Drug or Device Recall – June 12, 2 PM EDT – Moore →
In June, you have the unique opportunity to learn about how to avoid and manage FDA recalls from Dennis Moore,… Read more… →
GotoWebinar: Verification and Validation Planning and Execution – July 24, 1 PM EDT – Lincoln →
FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in many companies. One major failing is lack of… Read more… →
GotoWebinar: Bullet-Proof Closed-Loop CAPA, Failure Investigation, and Root Cause Analysis – June 5 – Lincoln →
A company's CAPA System is supposed to be a major tool in resolving product complaint, non-conformance, and focusing OOS failure… Read more… →
Enter your email address
"ExpertBriefings.com always selects excellent speakers – some of the best I have ever heard. Their messages are direct, clear, timely, and relevant."
Anon A. Mouse
